TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM -O Curriculum is produced by the EPEC TM Project with major funding.

Slides:



Advertisements
Similar presentations
Larissa Bornikova, MD July 17, 2006
Advertisements

The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong.
These are actual cases to –Stimulate your reading –Test your knowledge of the material Look for the sound icon (often in the upper right hand corner.
The management of empyema the practical vs. ideal approach R. Masekela University of Pretoria.
Dr. Ashraf A. Esmat A.Prof.Cardio-thoracic surgery Cairo university
Approach to Pleural Effusion
Rome, May 15-16, 2009 Enrico Cortesi, Martina Puglisi “Sapienza”, Università di Roma.
SVC Syndrome Sung Chul Hwang, M.D. Dept. of Pulmonary and Critical Care Medicine Ajou University School of Medicine.
Pleural Fluid Analysis. ll- pleural fluid analysis It comprises of -pleural fluid appearance - Biochemical tests ( Protein, LDH). -Cytological tests (
Indications for Thoracentesis
Management of Pleural effusions HUEH 2011 Terry Flotte, MD
Parapneumonic Effusions and Empyema
Diagnosis and Management of Malignant Pleural Effusion 衛生署桃園醫院內科加護病房主任莊子儀醫師 2006 年 7 月 20 日.
The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong.
DISEASES OF THE PLEURA.
Pleural Effusion.
Mesothelioma. Is a malignant tumour of pleura, usually resulting from asbestos exposure. Asbestos is the major single cause and there is a history of.
Chapter 25 Pleural Diseases
Pleural Effusion, Pneumothorax and Atelectasis
The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong.
Pleural Effusions.
Respiratory Pleural and Thoracic Injury. Pleural injury : Normal physiology- visceral, parietal pleura & pleural space.
Pneumothorax.
The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong.
The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong.
بسم الله الرحمن الرحیم با سلام.
Spontaneous Pneumothorax. Definitions Primary Spontaneous Pneumothorax (PSP)  No underlying lung disease Secondary Spontaneous Pneumothorax (SSP)  Complication.
Clinical Approach to PLEURAL EFFUSIONS.
Malignant Pleural Effusion (M.P.E.)
1 Mosby items and derived items © 2011, 2006 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 23 Effusion and Empyema Chapter 23 Pleural Effusion.
The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong.
Disorders of the Pleura and Mediastinum Dr. Gerrard Uy.
Pleural Disease.
The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong.
Chapter 16 Serous Fluid Professor A. S. Alhomida
Pleural fluid. Case study A 70-year-old women presents with slowly increasing dyspnea. She cannot lie flat without feeling more short of breath. She has.
Pleural Effusions Kara Lee Gallagher USC School of Medicine.
Pleural Effusion.
Day-case medical thoracoscopy
Para Pneumonic Effusion BY Professor Of Pediatrics, Head of Allergy & Clinical Immunology Unit - Mansoura University Egypt.
The history and physical examination are critical in guiding the evaluation of pleural effusion. Chest examination of a patient with pleural effusion –
Pleural effusion Riahi taghi,M.D.. Etiology Fluid formation: parietal pleura Fluid formation: parietal pleura Fluid removal: parietal pleura (lymphatic)
The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong.
Worcester and Wyre Forest Pleural Disease Service Dr. Clare Hooper Consultant Respiratory Physician Worcestershire Acute Hospitals NHS Trust.
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM -O Curriculum is produced by the EPEC TM Project with major funding.
Does This Patient Have a Pleural Effusion? Wong et al. University of Toronto JAMA January 21, 2009.
MEDICAL THORACOSCOPY IN THE DIAGNOSIS OF PLEURAL DISEASE “ …a minimum invasive technique which allows the examination of the pleural space in a spontaneously.
Pleural Effusions for the non- Chest Physician Dr Neil McAndrew Wrexham.
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM -O Curriculum is produced by the EPEC TM Project with major funding.
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM -O Curriculum is produced by the EPEC TM Project with major funding.
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM -O Curriculum is produced by the EPEC TM Project with major funding.
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM O Curriculum is produced by the EPEC TM Project with major funding.
Pleural Disease.
Complications related to Pneumothorax and Chylous Fluid Accumulation
Pleural Effusion Marvin Chang, PGY2 April 2015.
Effective Treatment of Malignant Pleural effusion by Minimal Invasive Thoracic Surgery: Thoracoscopic Talc Pleurodesis and Pleuroperitoneal shunt in 101.
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM -O Curriculum is produced by the EPEC TM Project with major funding.
TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC™-O Curriculum is produced by the EPEC TM Project with major funding.
Editor- Olufemi E. Idowu Copyright- Frontiers of Ikeja Surgery, 2016; 2:21 CLINICAL VIGNETTE OF THE MONTH -February 2016; 2:2.
1 Dr. SIRAJ WALI. 2 3 PLEURAL SPACE The pleura consists of 2 layers 1 – parietal pleura 2 – visceral pleura The space between the 2 layers is called.
Parapneumonic Effusion Meghan Flanagan, MD UW General Surgery R3 October 18, 2012.
Pleural Diseases Magdy Khalil MD, FCCP, EDIC
Malignant Pleural Effusion
Josephine Mak Waikato Cardiothoracic Unit
PLEURAL EFFUSION-EMPYEMA-PNEUMOTHORAX
wire-guided chest tube placement
دکتر فرزانه میرمحمدی متخصص طب اورژانس
Evaluation Pleural Effusions
Presentation transcript:

TM The EPEC-O Project Education in Palliative and End-of-life Care - Oncology The EPEC TM -O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong Foundation.

EPEC  – Oncology Education in Palliative and End-of-life Care – Oncology Module 3m: Module 3m: Symptoms – Malignant Pleural Effusions Symptoms – Malignant Pleural Effusions Module 3m: Module 3m: Symptoms – Malignant Pleural Effusions Symptoms – Malignant Pleural Effusions

Malignant pleural effusions... l Definition: fluid accumulation in the potential space between the visceral (inner) layer covering the lungs and the parietal (outer) layer covering the chest wall

... Malignant pleural effusions Symptoms: l Dyspnea l Cough l Chest pain l Decreased mobility and fear Symptoms: l Dyspnea l Cough l Chest pain l Decreased mobility and fear

Overview l Scope of the problem l Causes l Pathophysiology l Diagnosis l Prognosis l Management options l Treatment strategies l Scope of the problem l Causes l Pathophysiology l Diagnosis l Prognosis l Management options l Treatment strategies

Impact l More than 25% of newly diagnosed pleural effusions are due to malignancy l 50% of cancer patients will develop a pleural effusion l In US, approximately 100,000 malignant effusions/year occur l Life expectancy 4-12 months l More than 25% of newly diagnosed pleural effusions are due to malignancy l 50% of cancer patients will develop a pleural effusion l In US, approximately 100,000 malignant effusions/year occur l Life expectancy 4-12 months

Causes l Breast and lung cancer 50-65% l Lymphoma, GU, GI 25% l Unknown primary7-15% l Breast and lung cancer 50-65% l Lymphoma, GU, GI 25% l Unknown primary7-15%

Prognosis l Mortality 54% at 1 month, 84% at 6 months l Survival about 10 months where pleural effusion is first evidence of cancer l Known CA, exudate, negative cytology poor prognosis compared with positive cytology l Role of pH, Karnofsky Performance Scale? l Mortality 54% at 1 month, 84% at 6 months l Survival about 10 months where pleural effusion is first evidence of cancer l Known CA, exudate, negative cytology poor prognosis compared with positive cytology l Role of pH, Karnofsky Performance Scale?

Key points l Pathophysiology l Assessment l Management l Pathophysiology l Assessment l Management

Pathophysiology l Normally pleural fluid production equals fluid resorption l Effusion: Imbalance between fluid production and resorption l Causes: o Tumor cells blocking lymphatic drainage o Changes in colloid osmotic pressure due to hypoalbuminemia l Normally pleural fluid production equals fluid resorption l Effusion: Imbalance between fluid production and resorption l Causes: o Tumor cells blocking lymphatic drainage o Changes in colloid osmotic pressure due to hypoalbuminemia

Assessment l History of dyspnea, chest pain, cough l Physical examination of decreased breath sounds, dullness to percussion l History of dyspnea, chest pain, cough l Physical examination of decreased breath sounds, dullness to percussion

... Assessment l Symptoms: dyspnea, dry cough, pleuritic pain, chest discomfort, limited exercise tolerance l Exam: decreased breath sounds, dullness to auscultation and percussion l Chest X-Ray PA, lateral, and decubitus films l Chest CT or Ultrasound if loculated l Symptoms: dyspnea, dry cough, pleuritic pain, chest discomfort, limited exercise tolerance l Exam: decreased breath sounds, dullness to auscultation and percussion l Chest X-Ray PA, lateral, and decubitus films l Chest CT or Ultrasound if loculated

Differential diagnosis l Parapneumonic effusion l Empyema l Chylothorax l Transudate l Parapneumonic effusion l Empyema l Chylothorax l Transudate

Benign vs. malignant effusions... l Light’s criteria for exudates (one or more of following): 1. Pleural fluid LDH divided by serum LDH is greater than Pleural fluid protein divided by serum protein is greater than Pleural fluid LDH is greater than two- thirds upper limit of normal (ULN) of serum LDH l Light’s criteria for exudates (one or more of following): 1. Pleural fluid LDH divided by serum LDH is greater than Pleural fluid protein divided by serum protein is greater than Pleural fluid LDH is greater than two- thirds upper limit of normal (ULN) of serum LDH

... Benign vs. malignant effusions... l Heffner meta-analysis for exudates: 1. Pleural LDH is greater than 0.45 ULN 2. Pleural cholesterol is greater than 45 mg per dl 3. Pleural protein is greater than 2.9 g per dl Heffner 1997 l Heffner meta-analysis for exudates: 1. Pleural LDH is greater than 0.45 ULN 2. Pleural cholesterol is greater than 45 mg per dl 3. Pleural protein is greater than 2.9 g per dl Heffner 1997.

... Benign vs. malignant effusions l Cytology: o Positive for cancer in approximately 55 to 65% initially o Yield up to 77% positive on three pleural fluid samples l Cytology: o Positive for cancer in approximately 55 to 65% initially o Yield up to 77% positive on three pleural fluid samples

Management options l Thoracentesis l Tube thoracostomy l Small-bore chest tubes l Pleurodesis l Thoracoscopy l Intrapleural catheters l Pleuroperitoneal shunting l Subcutaneous access ports l Thoracentesis l Tube thoracostomy l Small-bore chest tubes l Pleurodesis l Thoracoscopy l Intrapleural catheters l Pleuroperitoneal shunting l Subcutaneous access ports

Management Intrapleural catheter Doxycycline pleurodesis Initial drainage 97%68% Pleurodesis46%54% Late recurrence 13%21% Complications 13% outpt 14% inpt

Thoracentesis l Diagnostic, therapeutic l Temporary relief l Many contraindications l Risks:  Pneumothorax  Re-expansion pulmonary edema (especially if more than 1500 cc removed) l Diagnostic, therapeutic l Temporary relief l Many contraindications l Risks:  Pneumothorax  Re-expansion pulmonary edema (especially if more than 1500 cc removed)

Treatment recommendations l Thoracentesis: diagnosis, palliation until more definitive procedure, medically ill, short-life expectancy l Tube thoracostomy: free-flowing effusions, unable to tolerate general anesthesia l Thoracoscopy: life expectancy greater than 3 months, loculated effusions, biopsies l Intrapleural catheters: outpatient pleurodesis l Thoracentesis: diagnosis, palliation until more definitive procedure, medically ill, short-life expectancy l Tube thoracostomy: free-flowing effusions, unable to tolerate general anesthesia l Thoracoscopy: life expectancy greater than 3 months, loculated effusions, biopsies l Intrapleural catheters: outpatient pleurodesis

Thoracoscopy benefits l Direct visualization of lung re-expansion l Identify loculated areas and drain l Administration of dry talc, chest tube placement l Confirm equal distribution of talc l Shorter hospital stay than tube thoracostomy l Diagnostic yield 90%, pleurodesis success rate 90% l Direct visualization of lung re-expansion l Identify loculated areas and drain l Administration of dry talc, chest tube placement l Confirm equal distribution of talc l Shorter hospital stay than tube thoracostomy l Diagnostic yield 90%, pleurodesis success rate 90%

Tube thoracostomy and pleurodesis... l More definitive than repeated thoracentesis for recurrent effusions l Chest tube 12 to 24 hours or until drainage is less than 250 ml per 24 hr l More definitive than repeated thoracentesis for recurrent effusions l Chest tube 12 to 24 hours or until drainage is less than 250 ml per 24 hr

... Tube thoracostomy and pleurodesis l Sclerosing agent: Use after fluid completely drained from pleural space o Talc, bleomycin, doxycycline o Tube clamping controversial o Rotation vs. nonrotation l Failure rate 10 to 40% l Most widely used and cost-effective method l Sclerosing agent: Use after fluid completely drained from pleural space o Talc, bleomycin, doxycycline o Tube clamping controversial o Rotation vs. nonrotation l Failure rate 10 to 40% l Most widely used and cost-effective method

Summary Use comprehensive assessment and pathophysiology-based therapy to treat the cause and improve the cancer experience.